Stanford University |
Anne Brunet |
Basic Biology IV |
Energy metabolism and aging pathways in human stem cell reprogramming and differentiation |
$1,414,044 |
Stanford University |
Michael Cleary |
Basic Biology IV |
Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells |
$1,244,455 |
University of California, Davis |
Deborah Lieu |
Basic Biology IV |
Induction of Pluripotent Stem Cell-Derived Pacemaking Cells |
$1,333,689 |
City of Hope, Beckman Research Institute |
Yanhong Shi |
Basic Biology IV |
Modeling Alexander disease using patient-specific induced pluripotent stem cells |
$1,366,656 |
University of California, San Francisco |
Miguel Ramalho-Santos |
Basic Biology IV |
Genetic dissection of human cellular reprogramming to pluripotency |
$1,184,883 |
University of California, San Diego |
Maike Sander |
Basic Biology IV |
Deciphering transcriptional control of pancreatic beta-cell maturation in vitro |
$1,258,560 |
Buck Institute for Age Research |
Deepak Lamba |
Basic Biology IV |
3D Modeling of Retina using Polymer Scaffolds for Understanding Disease Pathogenesis |
$1,212,553 |
Sanford Burnham Prebys Medical Discovery Institute |
Huei-sheng Chen |
Basic Biology IV |
Studying Arrhythmogenic Right Ventricular Dysplasia with patient-specific iPS cells |
$1,579,250 |
University of California, San Francisco |
Jeremy Reiter |
Basic Biology IV |
Modeling disease in human embryonic stem cells using new genetic tools |
$1,387,800 |
Stanford University |
Howard Chang |
Basic Biology IV |
Long noncoding RNAs for pluripotency and cell fate commitment |
$1,386,627 |
Stanford University |
Alexander Dunn |
Basic Biology IV |
Role of mechanical signaling in stem cell self-renewal and differentiation |
$1,062,998 |
Gladstone Institutes, J. David |
Steven Finkbeiner |
Basic Biology IV |
Common molecular mechanisms in neurodegenerative diseases using patient based iPSC neurons |
$1,395,184 |
University of California, San Diego |
George Sen |
Basic Biology IV |
Regulation of Epidermal Self-Renewal and Differentiation by Histone and DNA Demethylases. |
$1,080,000 |
Gladstone Institutes, J. David |
Benoit Bruneau |
Basic Biology IV |
Epigenetic regulation of human cardiac differentiation |
$1,568,148 |
University of California, Los Angeles |
Kathrin Plath |
Basic Biology IV |
Understanding the status of the X chromosomes in human ESCs and preimplantation embryos |
$1,382,400 |
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Development - Research |
Genetic Re-programming of Stem Cells to Fight Cancer |
$14,144,221 |
University of California, Davis |
John Laird |
Disease Team Therapy Development - Research |
Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia |
$3,728,384 |
University of California, Davis |
Nancy Lane |
Disease Team Therapy Development - Research |
Treatment of non-traumatic osteonecrosis with endogenous Mesenchymal stem cells |
$18,231,356 |
University of California, Davis |
Vicki Wheelock |
Disease Team Therapy Development - Research |
MSC engineered to produce BDNF for the treatment of Huntington's disease |
$8,924,235 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Disease Team Therapy Development - Research |
Progenitor Cells Secreting GDNF for the Treatment of ALS |
$16,168,464 |
Stanford University |
Joseph Wu |
Disease Team Therapy Development - Research |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$19,060,330 |
University of Southern California |
Andrew McMahon |
Research Leadership |
Repair and regeneration of the nephron |
$5,672,206 |
Stanford University |
Judith Shizuru |
Disease Team Therapy Development - Research |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$18,990,683 |
StemCells, Inc. |
Alexandra Capela |
Disease Team Therapy Development - Research |
Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy |
$8,901,641 |
Capricor, Inc |
Rachel Smith |
Disease Team Therapy Development - Research |
Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction |
$14,405,857 |
University of California, Irvine |
Henry Klassen |
Disease Team Therapy Development - Research |
Retinal progenitor cells for treatment of retinitis pigmentosa |
$17,144,825 |
University of California, Los Angeles |
Stanley Nelson |
Early Translational from Disease Team Conversion |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$1,823,545 |
University of California, Davis |
Walter Boyd |
Early Translational III |
Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair |
$4,631,754 |
University of California, San Diego |
Eric Adler |
Early Translational III |
Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease |
$1,701,575 |
University of Southern California |
Toshio Miki |
Early Translational III |
Generation of hepatic cell from placental stem cell for congenital metabolic disorders |
$1,750,375 |
University of California, San Francisco |
Arnold Kriegstein |
Early Translational III |
Human ES cell-derived MGE inhibitory interneuron transplantation for spinal cord injury |
$1,623,251 |
Stanford University |
Bertha Chen |
Early Translational III |
Autologous iPSC Therapy for Urinary Incontinence |
$4,715,738 |
University of California, San Diego |
Lawrence Goldstein |
Early Translational III |
Identifying Drugs for Alzheimer's Disease with Human Neurons Made From Human IPS cells |
$1,774,420 |
Children's Hospital of Orange County |
Philip Schwartz |
Early Translational III |
Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease |
$4,266,015 |
University of California, San Diego |
Yang Xu |
Early Translational III |
Human ES cell based therapy of heart failure without allogenic immune rejection |
$1,857,600 |
University of California, San Francisco |
Holger Willenbring |
Early Translational III |
Generation of safe and therapeutically effective human induced hepatocyte-like cells |
$1,544,170 |
University of California, San Francisco |
Morton Cowan |
Early Translational III |
Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID |
$3,862,367 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Early Translational III |
Direct Cardiac Reprogramming for Heart Regeneration |
$5,795,871 |
University of California, Davis |
Kyriacos Athanasiou |
Early Translational III |
Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells |
$1,735,703 |
City of Hope, Beckman Research Institute |
Stephen Forman |
Early Translational III |
Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,215,447 |
Scripps Research Institute |
Peter Schultz |
Early Translational III |
Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis |
$2,559,333 |
Stanford University |
Joseph Wu |
Early Translational III |
Heart Repair with Human Tissue Engineered Myocardium |
$4,395,080 |
Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Early Translational III |
Direct reprogramming towards vascular progenitors for the treatment of ischemia |
$2,340,000 |
University of California, Irvine |
Craig Walsh |
Early Translational III |
Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells |
$4,535,005 |
University of California, San Diego |
Mark Tuszynski |
Early Translational III |
Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury |
$4,600,447 |
University of California, San Diego |
Eugene Yeo |
Early Translational III |
Molecules to Correct Aberrant RNA Signature in Human Diseased Neurons |
$1,532,323 |
Salk Institute for Biological Studies |
David Schubert |
Early Translational III |
Stem cell based small molecule therapy for Alzheimer's disease |
$1,673,757 |
Stanford University |
Helen Blau |
Early Translational III |
Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients |
$1,825,283 |
University of California, Berkeley |
Song Li |
Conference |
University of California Systemwide Bioengineering Symposium 2012 |
$25,200 |
University of Southern California |
Kathy Rich |
Conference |
The Stem Cell Niche in Development and Regeneration |
$7,476 |
Cedars-Sinai Medical Center |
Clive Svendsen |
iPSC Consortia Award |
The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development |
$300,000 |
University of California, Santa Barbara |
Lina Kim |
Creativity Awards |
Research Mentorship Program-Immersing High School Students in College Research |
$280,726 |
Stanford University |
Paul Utz |
Creativity Awards |
SIMR Program: Stem Cell & Developmental Biology Research Internships |
$340,611 |
UCSF Benioff Children’s Hospital Oakland |
Vasanthy Narayanaswami |
Creativity Awards |
CHORI/UC Berkeley Summer Stem Cell Research Internship Program for High School Students |
$151,046 |
Scripps Research Institute |
James Williamson |
Creativity Awards |
Stem Cell Summer Academy: Creating the Next Generation of Scientists |
$205,122 |
University of California, San Francisco |
Katherine Nielsen |
Creativity Awards |
UCSF SEP High School Intern Program |
$168,947 |
University of California, Davis |
Gerhard Bauer |
Creativity Awards |
Internship at a Cutting Edge CIRM-funded Stem Cell Research Facility |
$250,064 |
City of Hope, Beckman Research Institute |
Paul Salvaterra |
Creativity Awards |
Creativity Award Program in Stem Cell Biology for California High School Students |
$260,825 |
Gladstone Institutes, J. David |
Shannon Noonan |
Creativity Awards |
Gladstone Summer Scholars (GSS) internship program |
$35,044 |
University of Southern California |
Roberta Brinton |
Creativity Awards |
CIRM STAR High School Summer Research and Creativity Program |
$271,160 |
Stanford University |
Thomas Rando |
Conference |
Keystone Symposia, 'The Life of a Stem Cell: From Birth to Death' |
$50,000 |
Buck Institute for Age Research |
Victoria Lunyak |
Conference |
Stem Cell Research and Aging |
$30,000 |
City of Hope, Beckman Research Institute |
Fouad Kandeel |
Conference |
2012 Rachmiel Levine Diabetes and Obesity Symposium: Advances in Diabetes Research |
$15,000 |
International Symposium on Neural Regeneration, Inc. |
Roger Madison |
Conference |
14th International Symposium on Neural Regeneration |
$20,000 |
City of Hope, Beckman Research Institute |
Richard Jove |
Conference |
Innovative Partnerships: Bringing Stem Cell Discoveries to the Clinic |
$14,994 |
Sanford Consortium for Regenerative Medicine |
Edward Holmes |
Conference |
Stem Cell Meeting on the Mesa: 6th Annual Scientific Symposium & 1st Annual Investor and Partnering Forum |
$40,000 |
University of California, Davis |
Alice Tarantal |
Conference |
10th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases |
$18,300 |
California Institute of Technology |
Paul Patterson |
Conference |
World Stem Cell Summit |
$50,000 |
Stanford University |
Albert Wong |
Disease Team Therapy Planning I |
Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma |
$109,750 |
Samumed, LLC |
John Hood |
Disease Team Therapy Planning I |
Clinical Development of an osteoinductive therapy to prevent osteoporosis-related fractures |
$99,110 |
Sanford Burnham Prebys Medical Discovery Institute |
Stuart Lipton |
Disease Team Therapy Planning I |
hESC-derived NPCs Programmed with MEF2C for Cell Transplantation in Parkinson’s Disease |
$96,448 |
Cedars-Sinai Medical Center |
Clive Svendsen |
Disease Team Therapy Planning I |
Stem Cells Secreting GDNF for the Treatment of ALS |
$63,487 |
University of Southern California |
Roberta Brinton |
Disease Team Therapy Planning I |
A CIRM Disease Team to Develop Allopregnanolone for Prevention and Treatment of Alzheimer's Disease |
$107,961 |
Stanford University |
Robert Robbins |
Disease Team Therapy Planning I |
Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$73,030 |
University of California, Davis |
Nancy Lane |
Disease Team Therapy Planning I |
Increasing the endogenous mesenchymal stem cells to the bone surface to treat osteoporosis |
$107,750 |
University of California, Davis |
Martin Birchall |
Disease Team Therapy Planning I |
Airways for Children |
$19,800 |
OncoMed Pharmaceuticals, Inc. |
Timothy Hoey |
Disease Team Therapy Planning I |
Anti-Notch1, OMP-52M51: A New Cancer Therapeutic to Reduce CSC Frequency |
$65,120 |
Sanford Burnham Prebys Medical Discovery Institute |
Marcel Daadi |
Disease Team Therapy Planning I |
Neural Stem Cell-Based Therapy For Parkinson’s Disease |
$63,952 |
Cedars-Sinai Medical Center |
Dan Gazit |
Disease Team Therapy Planning I |
Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. |
$107,622 |
University of California, Los Angeles |
Stanley Nelson |
Disease Team Therapy Planning I |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$68,947 |
University of California, Davis |
John Laird |
Disease Team Therapy Planning I |
Phase I study of IM Injection of VEGF Producing MSC for the Treatment of Critical Limb Ischemia |
$76,066 |
University of California, Davis |
Vicki Wheelock |
Disease Team Therapy Planning I |
MSC engineered to produce BDNF for the treatment of Huntington's disease |
$97,564 |
Stanford University |
Judith Shizuru |
Disease Team Therapy Planning I |
A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$90,147 |
University of California, Davis |
Mehrdad Abedi |
Disease Team Therapy Planning I |
Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients |
$66,880 |
StemCells, Inc. |
Alexandra Capela |
Disease Team Therapy Planning I |
Neuroprotection to treat Alzheimer's: a new paradigm using human central nervous system cells |
$90,101 |
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Planning I |
Genetic Re-programming of Stem Cells to Fight Cancer |
$97,785 |
University of California, Los Angeles |
Martina Wiedau-Pazos |
Conference |
California ALS Summit 2011 |
$13,300 |
University of California, San Diego |
Dong-Er Zhang |
Conference |
International RUNX Workshop |
$24,000 |
University of California, San Diego |
Rubén Flores |
Patent Assistance Fund Awards |
Patent Assistance Fund Application - UCSD |
$38,162 |
Stanford University |
Katharine Ku |
Patent Assistance Fund Awards |
Funding for Patent Applications for CIRM-funded Inventions out of Stanford University |
$3,525 |
University of California, Los Angeles |
Adele Rennie |
Patent Assistance Fund Awards |
Patent Assistance Fund - UCLA |
$84,973 |
University of California, Irvine |
Ronnie Hanecak |
Patent Assistance Fund Awards |
CIRM Patent Assistance Fund Application - UCI |
$46,155 |
University of California, Davis |
David McGee |
Patent Assistance Fund Awards |
CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies - UCD |
$48,595 |
University of California, San Francisco |
Karin Immergluck |
Patent Assistance Fund Awards |
Patent Assistance Fund Proposal - UCSF |
$87,257 |
University of California, Santa Barbara |
Bernadette McCafferty |
Patent Assistance Fund Awards |
Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara. |
$23,564 |
Human BioMolecular Research Institute |
John Cashman |
Patent Assistance Fund Awards |
Intellectual Property for Stem Cell-Related Inventions - HBRI |
$50,000 |
Brain Mapping Foundation |
Babak Kateb |
Conference |
8th Annual World Congress for Brain, Spinal Cord Mapping and Image Guided Therapy at Mission Bay Conference Center of UCSF School of Medicine |
$17,200 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Basic Biology III |
Mechanisms of Direct Cardiac Reprogramming |
$1,572,380 |
Scripps Research Institute |
Joel Gottesfeld |
Basic Biology III |
Triplet Repeat Instability in Human iPSCs |
$1,705,494 |
University of California, San Francisco |
Jason Pomerantz |
Basic Biology III |
Phenotypic Analysis of Human ES Cell-Derived Muscle Stem Cells |
$1,381,296 |